The debate on rare diseases: A look at media response


Rare diseases (RDs) are thosethat affect fewer than five people in every 10,000. There are around 7,000 RDs, they are difficult to diagnose and very few have a treatment. This article explores how the media report on the arguments and counter-arguments regarding the access to drugs for these pathologies, with critical discourse analysis for the case of Duchenne muscular dystrophy. We concluded that, in times of crisis, the debate polarises around economic arguments (the price of drugs), reinforced by doubts about their healing effectiveness.


critical discourse analysis; rare diseases; means of communication; argumentation; orphan drugs

Full Text:



Armayones, M., Requena, S., Gómez, B., Pousada, M., & Bañón, A. M. (2015). El uso de Facebook en asociaciones españolas de enfermedades raras: ¿Cómo y para qué lo utilizan? Gaceta Sanitaria, 29(5), 335–350. doi: 10.1016/j.gaceta.2015.05.007

Bañón, A. M., Fornieles, J., Solves, J. A., & Rius, I. (Coords.). (2011). Desafíos y estrategias comunicativas de las enfermedades raras. La investigación médica como referente. Valencia: CIBERER.

Bengoa, A. (2015, 15 August). Sydney ya tiene la medicina para frenar la enfermedad. El País. Retrieved from

Bengoa, A., & Sevillano, E. G. (2015a, 11 August). Mi hijo tendría el tratamiento adecuado fuera de Madrid. El País. Retrieved from

Bengoa, A., & Sevillano, E. G. (2015b, 12 August). La Comunidad promete ahora tratar al niño con síndrome de Duchenne. El País, p. 3.

Budych, K., Helms, T. M., & Schultz, C. (2012). How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient-physician interaction. Health Policy, 105(2–3), 154–164.

Comunidad de Madrid. (2015, 13 August). El niño con síndrome de Duchenne inicia hoy su tratamiento. Comunidad de Madrid. Retrieved from­ComunidadMadrid%2FEstructura

Cutillas, P., & Serrano, M. (2015, 11 August). Noticias La Sexta. [Television broadcast]. Madrid, Spain: La Sexta TV. Retrieved from

Douglas, C., Wilcox, E., Burgess, M., & Lynd, L. (2015). Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy, 119, 588–596. doi: 10.1016/j.healthpol.2015.01.009

Efe. (2015, 14 August). Los padres del niño que sufre Duchenne ya tienen el medicamento para su hijo. Efe. Retrieved from

Federación Española de Enfermedades Raras. (2009). Estudio sobre situación de necesidades sociosanitarias de las personas con enfermedades raras en España. Estudio ENSERio. Madrid: Caja Madrid.

Graf, J. M., & Frank, M. (2015). Rare is frequent and frequent is costly: Rare diseases as a challenge for health care systems. European Journal of Health Economics, 16, 113–118. doi: 10.1007/s10198-014-0639-8

Kesselheim, A., McGraw, S., Thompson, L., O’Keefe, K., & Gagne, J. (2015). Development and use of new therapeutics for rare diseases: Views from patients, caregivers, and advocates. Patient, 8, 75–84. doi: 10.1007/s40271-014-0096-6

Luzzatto, L., Hollak, C. E. M., Cox, T. M., Schieppati, A., Licht, C., Kääriäinen, H., & Remuzzi, G. (2015). Rare diseases and effective treatments: Are we delivering? The Lancet, 385(9970), 750–752. doi: 10.1016/S0140-6736(15)60297-5

Marqués, J. (2015, 28 July). La Sanidad está atendiendo a 185.000 inmigrantes como a cualquier español. El economista. Retrieved from

Picavet, E., Annemans, L., Cleemput, I., Cassiman, D., & Simoens, S. (2012). Market uptake of orphan drugs – a European analysis. Journal of Clinical Pharmacy and Therapeutics, 37, 664–667. doi: 10.1111/j.1365-2710.2012.01364.x

Picavet, E., Cassiman, D., & Simoens, S. (2014). Reimbursement of orphan drugs in Belgium: What (else) matters? Orphanet Journal of Rare Diseases, 9, 139. doi: 10.1186/s13023-014-0139-z

Rombach, S., Hollak, C. E. M., Linthorst, G., & Dijkgraaf, M. G. W. (2013). Cost-effectiveness of enzyme replacement therapy for fabry disease. Orphanet Journal of Rare Diseases, 8(1), 29. doi: 10.1186/1750-1172-8-29

Schlander, M., & Beck, M. (2009). Expensive drugs for rare disorders: To treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Current Medical Research and Opinion, 25(5), 1285–1293. doi: 10.1185/03007990902892633

Solves, J., Bañón, A., & Rius, I. (2015). El OBSER como centro impulsor de la investigación social de las enfermedades minoritarias. In C. Peñafiel, & J. L. Terrón (Coords.), Estudios de comunicación y salud (pp. 131–156). Tenerife: Cuadernos Artesanos de Comunicación.

The Lancet. (2015). Reducing the cost of rare disease drugs. The Lancet, 385(9970), 746. doi: 10.1016/S0140-6736(15)60420-2

Creative Commons License
Texts in the journal are –unless otherwise indicated– published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License